EUVIMEDEUVIMED entdecken
Crossref

Off-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Diseases

Aneesh Agarwal, Aisleen Diaz, Roudha Al-Dehneem, Raphaela Martina Pineda, Saakshi Khattri

Journal of Drugs in Dermatology · 01.12.2023 · 22 (12) · 1183-1190

DOI: 10.36849/jdd.7500 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Drugs in Dermatology, online erschienen am 01.11.2023. Verfasst von Aneesh Agarwal und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Crohn Disease, Hidradenitis Suppurativa, Dermatomyositis. Die Arbeit wurde bisher 16-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dysregulation of Janus kinase (JAK) pathways from uncontrolled cytokine signaling comprises the pathological basis for many complex inflammatory cutaneous disorders. Oral JAK inhibitors, upadacitinib, tofacitinib, and baricitinib targeting JAK 1 and JAK 1/3, respectively, are currently US Food and Drug Administration (FDA)-approved for several rheumatic conditions. However, studies have shown that JAK-mediated signaling pathways are involved in many immune-related dermatologic conditions. As a result, for recalcitrant diseases, JAK inhibitors are potential alternative therapies due to their broad targeted inhibitory mechanisms. In this case series, we present the successful off-label treatment of 6 cases across dermatomyositis, hidradenitis suppurativa, cutaneous lupus, and cutaneous Crohn’s disease, which failed conventional therapies with upadacitinib or tofacitinib. In the 3 dermatomyositis cases, use of upadacitinib or tofacitinib demonstrated positive clinical outcomes, with no recurrent symptoms in cases where upadacitinib was used. In treatment-resistant hidradenitis suppurativa, upadacitinib demonstrated reduced systemic flares and moderate cutaneous symptom improvement. In the case of cutaneous Crohn’s disease, upadacitinib resulted in reduced cutaneous symptoms without new flares. Tofacitinib resulted in completed resolution of cutaneous symptoms in our patient’s case of cutaneous lupus erythematosus. JAK inhibitors upadacitinib and tofacitinib may be potential drug candidates in patients with treatment-resistant disease, especially in cases of inflammatory cutaneous conditions such as dermatomyositis, hidradenitis suppurativa, cutaneous lupus, and cutaneous Crohn’s disease. Further studies with larger sample sizes among these conditions are warranted to assess potential broader applicability of the positive results demonstrated in our patient cases. J Drugs Dermatol. 2023;22(12):1183-1190. doi:10.36849/JDD.7500.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsCrohn DiseaseHidradenitis SuppurativaDermatomyositisDermatitisLupus Erythematosus, CutaneousHumansOff-Label UseJanus Kinases

Substanzen

Janus Kinase InhibitorsJanus Kinases

Zitieren

APA

Agarwal, A., Diaz, A., Al-Dehneem, R., Pineda, R. M., & Khattri, S. (2023). Off-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Diseases. Journal of Drugs in Dermatology, 22(12), 1183-1190. https://doi.org/10.36849/jdd.7500

Vancouver

Agarwal A, Diaz A, Al-Dehneem R, Pineda RM, Khattri S. Off-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Diseases. Journal of Drugs in Dermatology. 2023;22(12):1183-1190. doi:10.36849/jdd.7500

BibTeX
@article{Agarwal2023,
  author = {Agarwal, Aneesh and Diaz, Aisleen and Al-Dehneem, Roudha and Pineda, Raphaela Martina and Khattri, Saakshi},
  title = {Off-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Diseases},
  journal = {Journal of Drugs in Dermatology},
  year = {2023},
  volume = {22},
  number = {12},
  pages = {1183--1190},
  doi = {10.36849/jdd.7500}
}
Kostenlos starten →